Introduction
Cancer treatment is difficult due to plethora of unwanted side effects [1] . In present study, we have chosen 4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c] pyridine and 5,6-dihydro-1H-pyrazolo [3,4-c] pyridin-7(4H)-one as core structure as 4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c] pyridine is showing diversified biological activities as anticancer activity [2] , 5-HT6 inhibitors for pain treatment [3] , inflammatory disorders [4] , GnRH receptor antagonists [5] , kinase1 inhibitors [6] , cannabinoid receptors [7] , inhibitor of blood coagulation factor Xa [8] , PDE4 inhibitor [9] , COX-2 inhibitors [10] , antimicrobial [11] and P13K inhibitors [12] . The pyrazole is known for adenine mimetic pharmacophore and is useful in inhibitors of several classes of kinases like Aurora, CDK-2 and MAP kinases as these plays key role in drug discovery [2] . The tetrahydro-1H-pyrazole and their derivatives show diversifying activity. By considering their biological importance herein we report the synthesis of 3-(substituted)-4,5,6,7-tetrahydro-6-(substituted)-1H-pyrazolo [3,4-c] pyridine and 3-(substituted)-5,6-di hydro-6-(substituted)-1H-pyrazolo [3, 4-c] pyridin-7(4H)-one and anticancer activity in cell line along with kinase inhibition study. We have optimized routes for their synthesis. The synthetic methods adopted for the preparation of the title compounds 13a-h and 15a-h are depicted in Schemes 1 and 2 presented below.
Experimental

Reagent and instrumentation
All chemicals, unless otherwise specified, were purchased from commercial sources and were used without further purification. The major chemicals were purchased from Sigma Aldrich and Avra Labs. The development of reactions was monitored by thin layer chromatography (TLC) analysis on Merck pre-coated silica gel 60 F254 aluminum sheets, visualized by UV light. All reactions were carried out under argon inert atmosphere. Melting points were recorded on SRS OptiMelt. The purity of intermediates was pursued by TLC, NMR, and LC-MS. All final compounds and intermediates are characterized by NMR, LC-MS and purity of final compounds pursued by HPLC and all structures are consistent with proposed structures characterization. The 1 H NMR spectra were recorded on Varian NMR (400 MHz) spectrometer. The 13 C NMR spectra were recorded on Varian NMR (100 MHz) spectrometer. 
Scheme 1
The chemical shifts are reported as NMR spectra δppm units. The following abbreviations are used; singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m) and broad (br). Mass spectra were taken using Varian VG 7070 spectrometer at nominal 5000 resolution. The purity of final compounds was determined by HPLC on an Alltech Alltima C18 column (3.2 × 150 mm, 5 µM) eluting with 5-80% acetonitrile / 45 nM sodium bicarbonate.
Synthesis
Synthesis of tert-butyl-4-((dimethylamino)methyl ene)-3-oxopiperidine-1-carboxylate (2), Step (a)
To a stirred solution of N-tert-butoxycarbonyl-3-piperidone (1) (10.0 g, 50.2 mmol) in N,N-dimethylformamide dimethylacetal (50 mL). The reaction mixture was heated at 100 °C for 1 h. Progress of reaction was monitored by LC/MS for the consumption of starting material. After completion the reaction, the reaction mixture cooled to room temperature and evaporated under reduced pressure to obtain yellow gummy material. The obtained crude was diluted it with H2O (100 mL) and extracted it with EtOAc (2 × 50 mL). The organic layer was washed with H2O (50 mL) and brine (50 mL), dried it over anhydrous Na2SO4 to obtain yellow solid. The crude material was washed with 10% ethyl acetate:hexane (v:v, 10:90, 100 mL), hexane (100 mL) and diethyl ether (100 mL) to obtain compound 2. To a stirred solution of compound 2 (10.0 g, 39.4 mmol) was dissolved in ethanol (50 mL) and hydrazine hydrate (3.94 g, 78.7 mmol). The reaction mixture was heated at 80 °C for 8 h and the progress of reaction was monitored by LC-MS for the consumption of starting material.
Reagents and conditions: (a) KMnO4, 18-Crown-6, DCM, room temperature, 6 h, (general procedure); (b) 6 N HCl, room temperature, 6 h (general procedure).
Scheme 2
The reaction mixture was cooled to room temperature and evaporated under reduced pressure to obtain yellow gummy material. The obtained crude material was purified by silica gel (100-200 mesh) column chromatography by using 10-40% ethyl acetate:hexane (v:v, 10-40:90-60). The obtained compound was washed with diethyl ether (100 mL) to obtain compound 3 [13] . 
Synthesis of di-tert-butyl 4,5-dihydro-7H-pyrazolo [3,4-c]pyridine-1,6-dicarboxylate (4), Step (c)
To a stirred solution of compound 3 (5.00 g, 22.4 mmol) in DCM (50 mL), triethylamine (6.00 ml, 44.8 mmol) was added BOC anhydride (7.33 g, 33.6 mmol) and stirred reaction mixture to room temperature for 3 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. The obtained crude was washed with 10% ethyl acetate:hexane (v:v, 10:90) (25 mL), hexane (50 mL) and diethyl ether (50 mL) to obtain compound 4. Color: Yellow. Yield: 91 %, 6.6 g. M.p.: 55-56 °C. 1 H NMR (400 MHz, DMSO-d6, δ, ppm): 1.56 (s, 18H, N-(t-Bu)2), 2.21 (d, 2H, J = 6.2 Hz, CH2), 2.79 (m, 2H, CH2), 3.83 (s, 2H, N-CH2), 7.31 (s, 1H, Ar-H). 13 
Synthesis tert-butyl 4,5,6,7-tetrahydropyrazolo[3,4-c] pyridine-1-carboxylate (5), Step (d)
To a stirred solution compound 4 (6.50 g, 20.1 mmol) was dissolved in 2 N HCl (65 mL) and stirred reaction mixture to room temperature for 2 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. The obtained crude was washed with 10% ethyl acetate:hexane (v:v,10:90, 25 mL), hexane (50 mL) and diethyl ether (50 mL) to obtain compound 5. To a stirred solution compound 6 (5.00 g, 16.5 mmol) in 2 N NaOH (50 mL) and heat reaction mixture to 100 °C for 3 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. 
General procedure for synthesis of compounds 10a-d, Step (i)
To a stirred solution of compound 9 (1 mmol) in toluene (5 mL) was substituted aromatic boronic acid (2 mmol), 2-dicyclohexylphosphino-2,6-diisopropoxybiphenyl (0.2 mmol), cesium carbonate (3 mmol) and tris(dibenzylideneacetone) dipalladium(0) (0.2 mmol). The reaction mixture was purged with argon for 10 min and heat reaction mixture to 100 °C for 6 h. Progress of reaction was monitored by LC-MS. After completion the reaction, the reaction mixture was filtered through a pad of celite, washed with EtOAc (10 mL) and saturated cold sodium chloride solution (2×5 mL) and organic layer was evaporated under reduced pressure to obtain crude gummy material (10a-d). The obtained crude was purified by silica gel (230-400 mesh) by using ethyl acetate:heptane (15:85, v:v) to obtain compound 10a-d. [3,4- [3,4-c] 
Tert-butyl 3-(benzofuran-2-yl)-6-benzyl-4, 5, 6, 7-tetrahydro pyrazolo
Tert-butyl 3-(benzo[b]thiophen-2-yl)-6-benzyl-4, 5, 6,7-tetra hydropyrazolo
General procedure for synthesis of compounds (11a-d), Step (j)
To a stirred solution of compounds 10a-d (1 mmol) in methanol (10 mL) was added palladium on carbon (10 mol%) and keep the reaction in Parr Shaker apparatus by applying hydrogen gas pressure of 50 psi for 3 h at room temperature. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixtures filtered through a pad of celite and obtain filtrate evaporated under reduced pressure to obtain crude semisolid material for compound 11a-h. The obtained crude was washed with cold pentane and cold diethyl ether to obtain solid compounds 11a-h. [3,4-c] 
Tert-butyl 3-(benzofuran-2-yl)-4, 5, 6, 7-tetrahydropyrazolo
General procedure for synthesis of compounds (12a-h), Step (k)
To a stirred solution of compounds 11a-d (1 mmol) was dissolved in THF (10 mL). Then, added 2,6-lutidine (2 equiv.), DMAP (0.2 equiv.) and benzyl bromide (1.2 equiv.) and stirred reaction mixture to room temperature for 8 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. The obtained crude was washed with 20% ethyl acetate:hexane (v:v, 20:80), hexane and diethyl ether to obtain yellow semisolid compound. Crystallization of crude was done by using pentane and diethyl ether to obtain solid compounds 12a-h. [3,4-c] 
Tert-butyl 3-(benzofuran-2-yl)-4,5, 6, 7-tetrahydro-6-(3-met hoxyphenyl)pyrazolo
General procedure for synthesis of compound 13a-h, Step (l)
To a stirred solution of compounds 12a-h (1 mmol) was dissolved in 2 N dioxane in HCl (10 mL) and stirred reaction mixture to room temperature for 6 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. The crude obtained was washed with 10% ethyl acetate:hexane, hexane and diethyl ether to obtain crude 13a-h as yellow solid material. The crude was purified by column chromatography (silica gel, 230-400 mesh) by using 25-75% ethyl acetate and hexane to obtain desired compounds 13a-h as solid materials. [3,4-c] [3,4- [3,4- 
3-(Benzofuran-2-yl)-4, 5, 6, 7-tetrahydro-6-(3-methoxyphen yl)-1H-pyrazolo
3-(Benzo[b]thiophen-2-yl)-4,5, 6, 7-tetrahydro-6-(3-methoxy phenyl)-1H-pyrazolo
3-(Benzo[b]thiophen-2-yl)-4, 5, 6,7-tetrahydro-6-(pyrimidin-2-yl)-1H-pyrazolo
3-(4,5,6,7-Tetrahydro-6-(pyrimidin-2-yl)-1H-pyrazolo[3, 4-c]pyridin-3-yl)quinolone
General procedure for synthesis of compounds 14a-h, Step (a)
To a stirred solution of compounds 12a-h (1 mmol) was dissolved in DCM (10 mL). Then added KMnO4 (2 equiv.) and 18-crown-6 (0.5 equiv.) and stirred reaction mixture to room temperature for 6 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture was diluted with DCM (10 mL) and washed it with water (3×5 mL). Separated and collected the organic layer, washed it with 5 mL of brine and dried organic layer over anhydrous Na2SO4 and evaporated it under reduced pressure to obtain crude compounds 14a-h as semisolid compound. The crude obtained was washed with 5% ethyl acetate: hexane, hexane and diethyl ether to obtain yellow semisolid compound. The obtained compound was crystallized by using cold pentane and cold diethyl ether to obtain solid compounds 14a-h. [3,4- [3,4- [3, 4- [3, 4- 
Tert-butyl 3-(benzofuran-2-yl)-4,5,6,7-tetrahydro-6-(3-met hoxyphenyl)-7-oxopyrazolo
Tert-butyl 4, 5, 6, 7-tetrahydro-6-(3-methoxyphenyl)-7-oxo-3-(quinolin-3-yl)pyrazolo
Tert-butyl 4, 5, 6, 7-tetrahydro-7-oxo-6-(pyrimidin-2-yl)-3-(quinolin-3-yl)pyrazolo
Tert-butyl 4, 5, 6, 7-tetrahydro-7-oxo-6-(pyrimidin-2-yl)-3-(quinolin-5-yl)pyrazolo
General procedure for synthesis of compounds 15a-h, Step (b)
To a stirred solution of compounds 14a-h (1 mmol) was dissolved in 2 N dioxane in HCl (10 mL) and stirred reaction mixture to room temperature for 6 h. Progress of reaction was monitored by LC-MS for the consumption of starting material. After completion the reaction, the reaction mixture evaporated under reduced pressure to obtain yellow gummy material. The obtained crude was washed with 10% ethyl acetate: hexane, hexane and diethyl ether to obtain crude 15a-h as yellow solid material. The obtained compound was purified by column chromatography by using silica gel (230-400 mesh) by using 25-75% ethyl acetate and hexane to obtain desired compound 15a-h as solid materials. The anticancer activity test is performed according to the proce-dure developed by the National Cancer Institute (NCI, USA) in the 'In vitro Anticancer Drug Discovery Screen' that uses the protein-binding dye Sulforhodamine B (SRB) to assess cell growth [14, 15] . Briefly, cells are grown in 96-well plates in suspension and then exposed for 48 hours to four serial concentrations of 1×10 -7 , 1×10 -6 , 1×10 -5 , 1×10 -4 and 1×10 -3 M of each compound. Cells were fixed and stained with protein binding SRB stain. Excess stain is washed and bound stain was solubilized, and the absorbance was measured at 492 nm in a plate reader. Concentration of the compounds that inhibited 50% of the net cell growth, growth inhibition of 50% (GI50), was calculated from the dose response curve obtained for each test compound and cell line. GI50 values were presented in micro molar (μM) concentration. Doxorubicin was used as positive control for the comparison of cytotoxicity of synthesized compounds. Assays were performed in triplicate on three independent experiments and their mean values are taken as a final reading. The result of this study indicates that compound 13c, 13g, 15g and 15h shows prominent anticancer activity in all cell lines, having growth inhibition of 50 (GI50) values of 5.12 to 17.52 µM (Table 1) . All experiments were performed in duplicate and repeated three times.
3-(Benzofuran-2-yl)-5,6-dihydro-6-(3-methoxyphenyl)-1H
Results and discussion
Chemistry
In Scheme 1, Step (a) is enamine formation which is done by reacting compound 1 with DMF-DMA heating at 100 °C for obtaining compound 2 with 78% yield. The compound 2 is reacted with N2H4.H2O in EtOH at 80 °C for 8 h to obtain compound 3 with having 68.3% yield. The structure of 4,5,6,7-tetrahydro-1H-pyrazolo [4,3-c] pyridine is confirmed by singlet at δ 7.31 ppm in 1 H NMR [16] . Purification of the compound 3 required purification by using column chromatography. The overall yield obtained by this method is greater than earlier reports [13] . 4,5,6,7-Tetrahydro-1H-pyrazolo [4,3-c] pyridine (3) is reacted with di-tert-butyl dicarbonate (Boc anhydride) using triethylamine as base to obtain di-tert-butyl-4,5-di hydro-7H-pyrazolo [3,4-c] pyridine-1,6-dicarboxylate (4) with yield 91%. The compound 4 is having BOC protection on both nitrogen's confirmed by 1 H NMR showing singlet for 18 H at δ 1.56 ppm. The Step (d) is deportation of aliphatic N-BOC which is achieved by treating compound 4 with 2 N HCl for 2 h to obtain compound 5, confirmed by 1 H NMR showing singlet for 9 H at δ 1.56 ppm. The compound 5 was treated with pyridine Br2 at room temperature for 3 h to obtain compound 6 with 92% yield. The structure of tert-butyl-3-bromo-4,5,6,7-tetra hydropyrazolo [3,4-c] pyridine-1-carboxylate (6) was confirmed by disappearance of singlet at δ 7.31 ppm in 1 H NMR. The compound 6 reacted with aqueous NaOH in heating for 3 h. There is formation of compound 7 in 88.4% yield which is confirmed by desired mass in LC-MS. The compound 7 is protected by using benzylbromide in THF by using mixture of bases as 2,6-leutidine and DMAP at room temperature for compound 6h to obtain compound 8 with 83% yield, with 1 H NMR signals at δ 7.38-7.28 ppm (m, 5H). The compound 8 having free hydroxyl group which is protected by using triflic anhydride at room temperature for 12 h to obtain compound 9 with 88.5% yield. t-Butyl 3-(2,2,2-trifluoroacetoyloxy)-6-benzyl-4,5,6,7-tetrahydropyrazolo [3, 4-c] pyridine-1-carboxylate (9) is key intermediate for the synthesis of final compounds 13a-h and 15a-h. The compound 9 was treated with different aromatic boranic acids at 100 °C for 6 h to obtain compounds 10a-d with yields in the range from 63 to 83% yields after purifications by silica gel (100-200 mesh) column chromatography. Debenzylation of compounds 10a-d was done by using Pd/C in EtOH for 50 psi of hydrogen for 3 h at room temperature to obtain compounds 11a-d with 84 to 90% yields. Alkylation of compounds 11a-d was done by using substituted aromatic bromides in THF by using mixed bases 2,6-leutidine and DMAP for 3 h at room temperature to obtain compounds 12a-h with yields 84 to 93%. The cleavage of protecting group of compounds 12a-h was done by using aqueous 6 N HCl at room temperature for 6 h to obtain compounds 13a-h with yields 76 to 91%. The mixed bases used in Steps (g) and (k) to enhance the reactivity of secondary amine used for reaction.
In Scheme 2, compounds 12a-h are treated with KMnO4 in DCM and 18-crown-6 used as phase transfer catalyst at room temperature for 6 h to give compounds 14a-h with yields 71 to 78%, which is confirmed by vanishing singlet at 3.78 in 1 H NMR. The compound 14a-h are converted to compounds 15a-h by using aqueous 6 N HCl at room temperature for 6 h with 79 to 92% yields. The final compounds 13a-h and 15a-h are obtained with reaction yields 76 to 92%. Purity of all final compounds and key intermediates is >95% which are further used for biological activity studies. 13e, 13h, 15b, 15c, 15d, 15h .52 µM with pyrimidine and 3-yl-quinolone groups. The compound 15h having pyrimidine and 5-yl-quinolone groups is most active in MCF-7 cell line with IC50 value of 6.12 µM and A-549 with IC50 value of 9.13 µM also it is moderately active in HeLa and DU-145 cell lines with IC50 values of 14.16 and 11.62 µM, respectively. From cell line data compounds 13c, 13g, 15g and 15h are most active which are having pyrimidine-2-yl group and quinoline3/5-yl groups, compared with compounds having 3-methoxy phenyl, benzofuran and benzothiophene groups. The compound 13c is more active than compound 13d as both of these compounds are separated by position of nitrogen in the qunioline ring, the 3-methoxy compounds with benzofuran and benzothiophene are less active than compounds having pyrimidine-2-yl substitutions. Interestingly compounds having substituted 4,5,6,7-tetrahydro group and substituted 5,6-dihydro groups are moderate to active on all four cell lines and that substituted 5,6-dihydro groups are more active than that of substituted 4,5,6,7-tetrahydro group. These are results from both series of compounds. There is not much difference in their inhibitions in all four cancer cell lines. Further we have studied the most active compounds 13c, 13g, 15g and 15h on human kinases.
The compounds 13c, 13g, 15g and 15h are most active in cell line studies, so further we have tested for its activity against a panel of eight human kinase at 10 µM concentrations. For Aurora-A kinase compounds, they shows 73, 64, 51 and 57% inhibitions, respectively. The results are summarized in Table 2 . For Aurora-B kinase, compound 13c shows 41% inhibitions and for remaining compounds 13g (70%), 15g (77%) and 15h (73%) inhibitions. For CDK/cyclinA, CDK/cyclinE, EGFR and PDK1, the inhibition is in the range of 17 to 37%. CDK5/P25 kinase and mTOR kinase the inhibitions are in the range of 44 to 70%. For Aurora-A, Aurora-B, CDK5/P25 and mTOR kinase, all the compounds shows promising inhibitions to great extent. The inhibition results shows compound 13c is active for aurora-A kinase and CDK5/P25 kinase and it shows less inhibition for remaining kinases. Compounds 13g, 15g and 15h shows >50% inhibitions. For EGFR, PDK1, CDK2/ cyclinE and CDK2/cyclinA kinases, most of compounds shows <40% inhibitions.
Conclusion
We have synthesized 3-(substituted)-4,5,6,7-tetrahydro-6-(substituted)-1H-pyrazolo [3, 4-c] pyridine (13a-h) and 3-( substituted)-5, 6-dihydro-6-(substituted)-1H-pyrazolo [3, 4-c] pyridin-7(4H)-one (15a-h). The synthesis mainly required protection, deportation, N-alkylation and Suzuki coupling reactions. We have optimized all the steps for clean reaction profile and easy isolation of all intermediates and final compounds. The compounds 13a-h and 15a-h are tested for antiproliferative activity on panel of four cell lines. Compounds with pyrimidine-2-yl substitutions and quinolone 3/5-yl groups are most active compared with 3-methoxy and benzofurane/benzothiophene. Compounds 13c, 13g, 15g and 15h are tested for panel of eight kinase inhibitors and most of derivatives are mostly active on Aurora-A, Aurora-B, CDK5/P25 and mTOR human kinase inhibitors.
